Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3109/14397595.2016.1147405 http://scihub22266oqcxt.onion/10.3109/14397595.2016.1147405 C5020345!5020345!26873562     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mod+Rheumatol 2016 ; 26 (5): 667-71 Nephropedia Template TP {{tp|p=26873562|t=2016. Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan |pdf=|usr=}}{{26873562}} gab.com Text Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan JO: Mod Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=26873562 #FOAvip Objectives: To assess the effects of tocilizumab on pregnancy outcomes in Japanese patients with rheumatic disease.Methods: Data from Chugai?s tocilizumab safety database (April 2005 to October 2014) were retrospectively analyzed to identify pregnancy outcomes in patients exposed to tocilizumab.Results: Data were available for 61 pregnancies exposed to tocilizumab, and outcomes were reported for 50 of those pregnancies. In 36 births, no congenital anomalies were identified; however, six neonatal abnormalities were reported: five cases of low birth weight (<2500?g) and one case of neonatal asphyxia. Of 36 births, tocilizumab was resumed during lactation in two patients, with no subsequent adverse events reported in newborns. The spontaneous abortion rate was 18.0% (9 of 50 pregnancies), which is comparable to the rate in the general population. The five terminated pregnancies included one case of caudal regression syndrome.Conclusions: The present retrospective study of 61 pregnancies exposed to tocilizumab at conception indicated no increased rates of spontaneous abortion or congenital abnormalities in patients with rheumatic disease. However, further study is necessary to confirm the benefit-risk profile of tocilizumab treatment during pregnancy. Twit Text FOAVip Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan ????Mod Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=26873562 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26873562 #FOAvip English Wikipedia <ref>{{Cite pmid|26873562}}</ref> Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan #MMPMID26873562 Nakajima K; Watanabe O; Mochizuki M; Nakasone A; Ishizuka N; Murashima A Mod Rheumatol 2016[Sep]; 26 (5): 667-71 PMID26873562show ga Objectives: To assess the effects of tocilizumab on pregnancy outcomes in Japanese patients with rheumatic disease.Methods: Data from Chugai?s tocilizumab safety database (April 2005 to October 2014) were retrospectively analyzed to identify pregnancy outcomes in patients exposed to tocilizumab.Results: Data were available for 61 pregnancies exposed to tocilizumab, and outcomes were reported for 50 of those pregnancies. In 36 births, no congenital anomalies were identified; however, six neonatal abnormalities were reported: five cases of low birth weight (<2500?g) and one case of neonatal asphyxia. Of 36 births, tocilizumab was resumed during lactation in two patients, with no subsequent adverse events reported in newborns. The spontaneous abortion rate was 18.0% (9 of 50 pregnancies), which is comparable to the rate in the general population. The five terminated pregnancies included one case of caudal regression syndrome.Conclusions: The present retrospective study of 61 pregnancies exposed to tocilizumab at conception indicated no increased rates of spontaneous abortion or congenital abnormalities in patients with rheumatic disease. However, further study is necessary to confirm the benefit-risk profile of tocilizumab treatment during pregnancy. äPregnancy outcomes after exposure to tocilizumab: A retrospective anal(epmc).pdf DeepDyve Pubget Overpricing